Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.

@article{Steffens1999PhaseIR,
  title={Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250.},
  author={Martijn G Steffens and Otto C Boerman and Pieter H M de Mulder and Wim J. G. Oyen and Wilhelmina C A M Buijs and Johannes Alfred Witjes and Wim J M van den Broek and Jeannette C. Oosterwijk-Wakka and Frans M. J. Debruyne and Frans H. M. Corstens and Egbert Oosterwijk},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={1999},
  volume={5 10 Suppl},
  pages={3268s-3274s}
}
Clinical tumor targeting studies with chimeric monoclonal antibody G250 (cG250) in renal cell carcinoma (RCC) patients indicated the potential use of this antibody for radioimmunotherapy. Here we report on a phase I activity dose escalation study to determine the safety, the maximum tolerable dose (MTD), and the possible therapeutic potential of 131I-labeled cG250 in patients with progressive metastatic RCC. All patients (n = 12) received a diagnostic i.v. infusion of 5 mg of cG250 labeled with… CONTINUE READING
36 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Molecular characterization of the renal cell carcinoma associated antigen G250

  • E. Oosterwijk, M. de Weijert, A. van Bokhoven, R. H. Brakenhoff, W. P. Peelen, F.M.J. Debruyne
  • Urol. Res.,
  • 1995
1 Excerpt

Similar Papers

Loading similar papers…